Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy

被引:2
|
作者
Varghese, Treesa P. [1 ]
John, Anish [2 ]
Mathew, Jithin [2 ]
机构
[1] Yenepoya Deemed Be Univ, Yenepoya Pharm Coll & Res Ctr, Dept Pharm Practice, Mangalore 575018, Karnataka, India
[2] NITTE Deemed Be Univ, NGSM Inst Pharmaceut Sci, Dept Pharmaceut, Mangalore, Karnataka, India
来源
PRECISION RADIATION ONCOLOGY | 2024年 / 8卷 / 03期
关键词
radiopharmaceutical therapy; radiopharmaceuticals; quality control; scintigraphy; RADIATION;
D O I
10.1002/pro6.1239
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Radiopharmaceutical therapy (RPT) is a precision medicine approach that involves the targeted delivery of radioactive atoms to tumor cells, representing a breakthrough strategy for cancer treatment. Radiopharmaceuticals typically consist of a small amount of radioactive material, a radionuclide, paired with a chemical that specifically targets the cell. Some radionuclides naturally target specific cells or biological processes without the need for modification. RPT is a novel cancer treatment method that offers various advantages over current traditional treatment approaches. One of the primary advantages of RPT is its ability to target cancer cells, including those in metastatic areas. Another key advantage of RPT is that radiation can be delivered systemically, locally, or physiologically to specific cells internally rather than being applied externally. Moreover, radiotracer imaging can be utilized to determine radiopharmaceutical absorption in target tissues before providing a therapeutic dose. Compared to all other cancer treatment approaches, RPT has demonstrated high efficacy with minimal toxicity. The recent approval of multiple RPT medicines by the US Food and Drug Administration highlights the tremendous potential of this treatment. This article provides a detailed review of RPT, including insights into manufacturing procedures, safety measures, and its applications in cancer therapy. Steps involved in the preparation of radiopharmaceuticals image
引用
收藏
页码:145 / 152
页数:8
相关论文
共 50 条
  • [42] Biological Carrier Molecules of Radiopharmaceuticals for Molecular Cancer Imaging and Targeted Cancer Therapy
    Aerts, A.
    Impens, N. R. E. N.
    Gijs, M.
    D'Huyvetter, M.
    Vanmarcke, H.
    Ponsard, B.
    Lahoutte, T.
    Luxen, A.
    Baatout, S.
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (32) : 5218 - 5244
  • [43] Radiopharmaceuticals in therapy and monitoring of patients with medullary thyroid cancer
    Solodyannikova, O.
    Sukach, G.
    Tratsevsky, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S349 - S349
  • [44] The role of radiation therapy in the treatment of esophagus cancer
    Bruce D. Minsky
    Esophagus, 2003, 1 (1) : 5 - 15
  • [45] The role of radiation therapy in the treatment of metastatic cancer
    Stea, Baldassarre
    Skrepnik, Tijana
    Hsu, Charles C.
    Abendroth, Roy
    CLINICAL & EXPERIMENTAL METASTASIS, 2018, 35 (5-6) : 535 - 546
  • [46] The role of radiation therapy in the treatment of metastatic cancer
    Baldassarre Stea
    Tijana Skrepnik
    Charles C. Hsu
    Roy Abendroth
    Clinical & Experimental Metastasis, 2018, 35 : 535 - 546
  • [47] Role of photodynamic therapy in the treatment of esophageal cancer
    Wu, Hao
    Minamide, Tatsunori
    Yano, Tomonori
    DIGESTIVE ENDOSCOPY, 2019, 31 (05) : 508 - 516
  • [48] CANCER DIAGNOSIS - ROLE OF TUMOR-IMAGING RADIOPHARMACEUTICALS
    SILBERSTEIN, EB
    AMERICAN JOURNAL OF MEDICINE, 1976, 60 (02): : 226 - 237
  • [49] Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies
    Raghani, Neha R.
    Chorawala, Mehul R.
    Mahadik, Mayuresh
    Patel, Rakesh B.
    Prajapati, Bhupendra G.
    Parekh, Priyajeet S.
    MEDICAL ONCOLOGY, 2024, 41 (02)
  • [50] Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies
    Neha R. Raghani
    Mehul R. Chorawala
    Mayuresh Mahadik
    Rakesh B. Patel
    Bhupendra G. Prajapati
    Priyajeet S. Parekh
    Medical Oncology, 41